Brain Tumors Research

City of Hope is a hub of innovation and progress when it comes to treating brain tumors. Our research and clinical teams work together to advance therapies that more effectively — and directly — target brain tumors. A groundbreaking case study conducted at City of Hope, and published in the New England Journal of Medicine, found that using CAR T cell therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma. And we are researching immunotherapy as a way of disabling cancer cells and finding unique ways to allow cancer drugs to cross the blood-brain barrier.

We are world leaders in the field of neural stem cell therapy, a groundbreaking method of delivering chemotherapy drugs directly to tumor sites within the brain — and were the first in the world to apply this exciting breakthrough therapy to brain cancer.

Brain Tumor Clinical Trials

The key to finding better treatments for aggressive disease is the constant collaboration between researchers, clinicians and oncologists — who move therapies swiftly from our on-campus research labs to patients. The quality and frequency of this interaction allows us to get potentially life-extending therapies to our patients quickly.

For more information about the brain tumor studies listed below, including eligibility criteria, please call: 844-333-HOPE (4673). For a summary of these studies, visit the City of Hope clinical trials website.

Newly Diagnosed Gliomas

NCT04164901If you're newly diagnosed with gliomas, you may participate in a study using vorasidenib (AG-881) to treat residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation (INDIGO).

Principal investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 12 years or older
  • Diagnosed with a residual, recurrent or grade 2 glioma and an IDH1 or IDH2 mutation
  • May have undergone surgery as part of a previous anti-cancer treatment.

Learn More About This Promising Study

NCT04471844We're recruiting for a study evaluating the benefits and safety of glioblastoma-treating medical device Optune given concomitantly with radiation therapy (RT) and temozolomide (TMZ) or RT and TMZ alone.

Principal investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Newly diagnosed with gliomas

Learn More About This Promising Study

Glioblastoma

NCT03776071We're recruiting patients with newly diagnosed glioblastoma (high-grade gliomas) in a randomized study on treatment with enzastaurin alone or enzastaurin plus temozolomide to weigh the benefits of combinatory therapy.

Principal investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with high-grade gliomas

Learn More About This Promising Study

Recurrent Gliomas/Glioblastoma

NCT04214392: We're recruiting for a study on the possible benefits and optimal doses of CAR T cells with a chlorotoxin tumor-targeting domain to treat MPP2+ recurrent or progressive glioblastoma.

Principal investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent or progressive glioblastoma

Learn More About This Promising Study

NCT03389230: If you've been diagnosed with recurrent or refractory high-grade gliomas, you may participate in a study using memory-enriched T cells — specifically, HER2 (EQ) BBᶳ/CD19 t+ T cells aimed at killing glioma tumor cells.

Principal investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age from 18 to 75 years old
  • Diagnosed with recurrent or refractory high-grade gliomas and HER2+

Learn More About This Promising Study

NCT04003649: We're recruiting for a study on treatment using CAR T cells or CAR T cells plus monoclonal antibody drugs, nivolimab and ipilimumab.

Principal investigator: Behnam Badie, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with high-grade glioblastoma

Learn More About This Promising Study

NCT02192359We're recruiting for a study to assess the potential benefits of neuro-stem cells treatment for recurrent high-grade gliomas.

Principal investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age from 18 to 69 years old
  • Diagnosed with high-grade gliomas

Brain Metastases

NCT0369603: We're recruiting for a study to evaluate the possible benefits of HER2-CAR T cells in treating patients with recurrent brain or leptomeningeal metastases.

Principal investigator: Jana Portnow, M.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age from 18 to 75 years old
  • Diagnosed with brain metastases and HER2+

Leptomeningeal glioblastoma, ependymoma or medulloblastoma

NCT04661384: Patients with leptomeningeal metastases may participate in a study to assess the benefits of treatment using brain tumor-specific immune cells.

Principal investigator: Lisa Feldman, M.D., Ph.D.

Clinical Trials Icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with leptomeningeal metastases from glioblastoma, ependymoma or medulloblastoma

Learn More About This Promising Study

Coming soon

A Phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated glioblastoma or other primary central nervous system tumors harboring activating FGFR1-3 alterations (FIGHT-209)

Principal investigator: Jana Portnow, M.D.